SymBio, Eisai sales and marketing update

Eisai launched Symbenda bendamustine in Singapore to treat low-grade non-Hodgkin's lymphoma (NHL) and chronic lymphatic leukemia (CLL). SymBio, which has rights to the alkylating agent in Japan, China, Korea, Taiwan and Singapore from Astellas Pharma Inc. (Tokyo:4503, Tokyo, Japan), granted Eisai exclusive rights in Singapore and South Korea in 2009. Eisai also has rights under a 2008 deal with SymBio to co-develop and exclusively commercialize bendamustine in Japan. ...